Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Aankoop patent eiwitcomplexen immunologie
Volgen
cqtvld schreef op 26 augustus 2015 08:07 :
Op een ander forum hebben we afgesproken om niet meer te reageren op deze persoon, wij hebben nu geen last meer van hem .Deal.Voor de rest allemaal succes.
Welk forum is dat...??? Of durf je dat niet te vertellen...??
-24 cent over een paar weken is dit een pennystock bedankt Amar dat je de boel weer hebt belazerd, maar je zal er niet mee zitten
Dat denk ik ook dat het een pennuystock gaat worden
Vitavita schreef op 17 oktober 2015 17:02 :
kom deze tegen:
www.presspeople.com/nota/uso-exomas-d... Dank voor het plaatsen.
Vitavita schreef op 17 oktober 2015 17:02 :
kom deze tegen:
www.presspeople.com/nota/uso-exomas-d... Wat goed ze zijn verder dan dat wij denken.
Nu effe in het Nederlands;)
Vitavita schreef op 17 oktober 2015 17:02 :
kom deze tegen:
www.presspeople.com/nota/uso-exomas-d... AB Mooi bericht en goed gevonden. Waar Bing al niet goed voor is...
Met behulp van exome afkomstige stamcellen en hun medische toepassingen. Vrijdag 16 oktober, 2015, 09:52Door Cryo-Cord Een jaar geleden, uit Chili de vroege ontwikkeling van een behandeling voor het aankondigen voorkomen hersenverlamming gebruiken exome uit mesenchymale stamcellen. Hersenverlamming veroorzaakt door permanente schade aan de hersenen die eerder heeft plaatsgevonden, tijdens of na de bevalling. De ontwikkeling doel was om een behandeling die de referentie-regeneratie van hersengebieden eerder getroffen dan alleen de behandeling van de symptomen als gevolg van deze blessures beïnvloedt bieden. In dezelfde geest, in 2015, CryoSave (Crio-Cord in Spanje), de bank de biologische Esperite Group, reeds een behandeling voor de ziekte bij 7 kinderen die hun hadden stamcellen gecryopreserveerd in de celbank. In dit geval hebben we gebruik gemaakt van stamcellen uit het bloed en navelstrengweefsel. Na deze stappen heeft Esperite een nieuwe stap voorwaarts voor zover stamcel behandelingen betreft genomen. De groep heeft net de rechten van een internationaal octrooi voor het gebruik van exoom van mesenchymale stamcellen in gebruik bij de behandeling van ontstekings- en auto-immuunziekten. Deze extracellulaire blaasjes genaamd exome, waarvan de belangrijkste missie is om de communicatie tussen cellen te vergemakkelijken. Bovendien reguleren ze celprocessen door immuuncellen (vooral lymfocyten B). Tot nu toe zijn exoom klinisch toegepast (vooral belangrijk in kankerdiagnose) biologische markers en drugs vervoeren naar specifieke gebieden, waardoor de noodzakelijke dosis verminderen daarvan en dus de bijwerkingen te verminderen. Door het opnemen van dit gebruik van de regeneratieve geneeskunde exome, zal combineren die eigenschappen immunomodulerende middelen en het regeneratievermogen van mesenchymale cellen. Dus met dit octrooi kan worden behandeld ontstekingsziekten zoals reumatoïde artritis en andere bindweefsel, ziekte van Crohn of type 1 diabetes onder anderen. Maar ook toepassing bij de preventie van transplantaatafstoting vinden, aangezien het exoom stimuleert het proces van tolerantie en vermindering van de immuunrespons. Het octrooi voor deze technologie werd ontwikkeld aan de Bambino Gesù ziekenhuis in Rome en eerste klinische applicatie in acute inflammatoire neurologische aandoeningen en anderen, zoals ruggenmergletsel, hersenletsel of neonatale e
Maar ook toepassing bij de preventie van transplantaatafstoting vinden, aangezien het exoom stimuleert het proces van tolerantie en vermindering van de immuunrespons. Het octrooi voor deze technologie werd ontwikkeld aan de Bambino Gesù ziekenhuis in Rome en eerste klinische applicatie in acute inflammatoire neurologische aandoeningen en anderen, zoals ruggenmergletsel, hersenletsel of neonatale encefalopathie, zal het eerste onderzoek zijn.
Lees ook even in de telegraaf beurs goeroes Robert Schuckink kool.
tiekoes1 schreef op 9 maart 2016 11:40 :
Lees ook even in de telegraaf beurs goeroes Robert Schuckink kool.
...jammer, dat Esperite niet genoemd wordt..
Gelukkig nog niet anders kon ik niet meer bijkopen op deze lage koers.
Esperite (ESP) leads international consortium for clinical translation of extracellular vesicles use in various therapies September 30, 2016 Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies. Esperite’s business unit The Cell Factory develops EVs-based therapeutics in treatment of drug-resistant epilepsy in children jointly with Bambino Gesu` Children’s Hospital, Mario Negri Institute for Pharmacological Research and the Women’s and Children’s Health Department of the University of Padua. Esperite N.V. (Euronext: ESP, “Esperite”) sponsors an international consortium of the leading teams in paediatric regenerative medicine to bring extracellular vesicles (EVs) technology to the clinic with niche applications in treatment of severe neuro-inflammatory diseases. Its first project focuses on EVs application in untreatable-yet acute and chronic drug-resistant epilepsy in children. The consortium will also investigate EVs and exosomes characteristics, potency, and a mode of action and will further improve the EVs production processes. Led by Professor Federico Vigevano at Bambino Gesu` Children’s Hospital with Dr Alessandra Fierabracci providing her expertise in Immunology and Dr. Annamaria Vezzani at Mario Negri Institute, pre-clinical tests of mesenchymal stem cells (MSC)-derived EVs are underway to confirm the safety and efficacy already demonstrated in multiple in vitro and in vivo models. This project will enable the first-in-man use of MSC-derived EVs and exosomes in treatment of drug-resistant epilepsy in children. The project follows a long-term collaboration between the Children’s Hospital and the Esperite group initiated and liaised by Professor Stefano Grossi, Esperite’s Scientific Director in Italy. In parallel, Esperite’s regenerative medicine division, The Cell Factory, in partnership with Professor Maurizio Muraca’s team at University of Padua, are better characterising EVs to establish clinical grade standards for production, purification, quantification, bio-distribution and molecular characterisation of new EV-based therapeutics. Professor Muraca has also agreed to join the Scientific Board of The Cell Factory to support EVs products development and clinical translation. Professor Muraca has extensive and long-term experience in immunology, EVs and MSCs research, and the expertise in regulations of advanced therapies use in clinic. The Cell Factory produces ultra-pure EVs and exosomes according to GLP/GMP guidelines, using proprietary technology for expansion of MSC in fully defined media with no use of animal-derived components at any stage. Stem cells expansion is performed in the most efficient and scalable 3D culture systems using microcarrier beads. The Cell Factory’s proprietary closed cell culture system produces high purity EVs and exosomes using pharmaceutical-quality sequential filtration system for EVs extraction and purification. The system can be easily scaled up improving significantly EVs production costs, footprint and process scalability. EVs products can be manufactured with this technology at least 10x more efficiently and cheaper when comparing to MSC equivalent. The consortium will investigate the anti-inflammatory and anti-epileptic effect of the “off-the-shelf” EVs derived from non-HLA-matched MSC lines. The advantages of using EVs in treatment of acute and chronic epilepsy are product stability and low production costs providing the “off-the-shelf” drug for immediate and repeated non-invasive application. In a broader perspective, the positive results of using immunosuppressive EVs in a central nervous system would open up a possibility of immediate intervention in acute diseases in neurology such as stroke, traumatic brain, spinal cord injury, newborn hypoxic ischemia and many others. Diseases of central nervous system are among most devastating for patients and their relatives. Neurological disorders are generating a significant additional cost related to hospitalisation, rehabilitation, often eliminate the patients and their relatives from a job market. CDC estimated that annual costs related to epilepsy exceeds 15 billion USD in the United States alone with 50 million patients worldwide (WHO). Cost related to brain stroke in the United States is estimated to 34 billion USD per year (CDC), with 15 million new patients worldwide each year (WHO). Cumulative cost related to traumatic brain injury (TBI) and spinal cost injury in the United States is over 80 billion USD per year (CDC and AANS), with up to 0.5 million new incidents of spinal cord injury and 10 million of TBI per year (WHO). Most of these diseases have no effective therapy yet. It is expected that EVs products will be effective in the niche indications of above-mentioned conditions preventing neuroinflammatory-related damage of central nervous system. Moreover, EVs will be able to target an acute diseases i.e. TBI, brain stroke, spinal cord injury, more effectively when comparing to allogenic MSCs, due to the EV’s stability and easier administration at shorter time what is critical for successful therapy. The latter would additionally expand a potential market of EVs products beyond the competitive allogenic MSCs products. Epilepsy is one of the most common brain diseases affecting about 1 in 100 children under 17-year old according to CDC. Epilepsy carries significant detrimental effects on the quality of life and can lead to a secondary brain damage. The disease can have different aetiology, including stroke, brain trauma, and neuro-inflammation. Severity of the seizures is variable and the antiepileptic drugs are effective only in about 2/3 of the patients.
Vervolg:About the consortium partners: Ospedale Pediatrico Bambino Gesu´ OPBG (Rome, Italy) is the largest paediatric Hospital and research center in Europe, providing over 1.550.000 healthcare services each year to children and adolescents from all over the world. OPBG pursues excellency in health care through advanced research and clinical activities, while improving processes to exploit the progress of biomedical science. The Hospital’s clinical activities run side by side with its sci- entific research, aiming at constantly improving and innovating diagnostic and therapeutic procedures. OPBG’s Research Laboratories are located in a 5,000 sqm research facility, fully equipped with high-tech systems, supporting genomics, metagenomics, metabolomics, pro- teomics, microarray technology, cytogenetic and FISH applications, cytofluorimetry and cell sorting, cell and molecular biology. Within the Research Laboratories the team led by the Immunologist Dr Alessandra Fierabracci has established potency assays for evaluating the immunomodulatory activity of MSC-derived exosomes in vitro.The IRCCS-Istituto di Ricerche Farmacologiche “Mario Negri” (www.marionegri.it) in Milan, Italy is a non-profit biomedical research institute. The Institute’s constant research areas include cardiovascular, psychiatric and neurological diseases, and tumours. Over the years, in line with technical advances, research has spread into the fields of environment and health, kidney diseases, organ transplantation, and rare diseases, The Institute works regularly with various associations, hospital groups with different specialties, general practitioners, and nurses, setting up nation-wide cooperation networks. Underlying all this is basic research in pharmacokinetics, pharmacology, immunology, cell biology, genomics, proteomics, and metabolomics; it organizes controlled randomized clinical trials, studies on cohorts of elderly people, systemic reviews and meta-analyses. Dr Annamaria Vezzani is Head of the Laboratory Experimental Neurology, Dept of Neuroscience, and she will be contributing to the project by sharing her long standing expertise with animal models of epilepsy and neuroinflammation to test the therapeutic anticonvulsive potential of extracellular vesicles and provide proof-of-concept evidence for clinical applications.The department of Woman’s and Child’s Heath of the University of Padua is a 269-bed tertiary paediatric academic care centre, serving the entire North East region of Italy, devoted to provide excellence in patient’s care, teaching and research, also including a ten-store research building. It is one of the eleven fully recognised Italian Children’s Hospitals. The University of Padova was founded in 1222. It includes 32 Departments, 1 University Hospital, 1 Veterinary Hospital, 1 Experimental Farm, 1 School of Excellence. It counts 61,000 Students and 12,000 Graduates per year.
Uitgelicht: ..... Led by Professor Federico Vigevano at Bambino Gesu` Children’s Hospital with Dr Alessandra Fierabracci providing her expertise in Immunology and Dr. Annamaria Vezzani at Mario Negri Institute, pre-clinical tests of mesenchymal stem cells (MSC)-derived EVs are underway to confirm the safety and efficacy already demonstrated in multiple in vitro and in vivo models. This project will enable the first-in-man use of MSC-derived EVs and exosomes in treatment of drug-resistant epilepsy in children. The project follows a long-term collaboration between the Children’s Hospital and the Esperite group initiated and liaised by Professor Stefano Grossi, Esperite’s Scientific Director in Italy. ......
Esperite geeft aan dat er een nieuw productielijn in de maak is, waarbij Esperite de capaciteit en kwaliteit ( mede door inbreng van de genoemde medici) kan leveren in deze nieuwe bio-industrie: ... The consortium will also investigate EVs and exosomes characteristics, potency, and a mode of action and will further improve the EVs production processes ... ... The Cell Factory, in partnership with Professor Maurizio Muraca's team at University of Padua, are better characterising EVs to establish clinical grade standards for production, purification, quantification, bio-distribution and molecular characterisation of new EV-based therapeutics. ... ... Professor Muraca has also agreed to join the Scientific Board of The Cell Factory to support EVs products development and clinical translation ... ... The Cell Factory produces ultra-pure EVs and exosomes according to GLP/GMP guidelines, using proprietary technology for expansion of MSC in fully defined media with no use of animal-derived components at any stage. Stem cells expansion is performed in the most efficient and scalable 3D culture systems using microcarrier beads. The Cell Factory's proprietary closed cell culture system produces high purity EVs and exosomes using pharmaceutical-quality sequential filtration system for EVs extraction and purification. The system can be easily scaled up improving significantly EVs production costs, footprint and process scalability. EVs products can be manufactured with this technology at least 10x more efficiently and cheaper when comparing to MSC equivalent ... Wordt later dit weekend vervolgd bij immunologie draadje .
Tigenix richt zich op: "....is an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic , or donor-derived, expanded stem cells.Esperite (The Cell Factory) richt zich al op de volgende technologische ontwikkeling: "..Moreover, EVs will be able to target an acute diseases i.e. TBI, brain stroke, spinal cord injury, more effectively when comparing to allogenic MSCs, due to the EV’s stability and easier administration at shorter time what is critical for successful therapy. The latter would additionally expand a potential market of EVs products beyond the competitive allogenic MSCs products ." Inclusief: "Extracellular vesicles (EVs) disruptive technology targets unmet needs in neuroinflammatory diseases at lower costs than allogenic stem cell therapies ."
Professor Federico Vigevano , belangrijke inetrantioanle onderscheiding in september 2016 voor klinische en wetenschappelijke activiteiten m.b.t.epilepsie. translate.google.nl/translate?hl=nl&a... Maurizio Muraca en Alessandra Fierabracci zijn de schrijvers/uitvinders van de 2 aangekochte patenten in 2015.Annamaria Vezzani Research Immunity and Inflammation in Epilepsy
Vitavita schreef op 2 oktober 2016 15:41 :
Professor
Federico Vigevano , belangrijke inetrantioanle onderscheiding in september 2016 voor klinische en wetenschappelijke activiteiten m.b.t.epilepsie.
translate.google.nl/translate?hl=nl&a... Maurizio Muraca en
Alessandra Fierabracci zijn de schrijvers/uitvinders van de 2 aangekochte patenten in 2015.
Annamaria Vezzani Research Immunity and Inflammation in Epilepsy
ahum, inetrantioanle = internationale..... letters op een rijtje zetten ;-)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
867,29
-0,77%
EUR/USD
1,0686
-0,11%
FTSE 100
8.066,33
+0,32%
Germany40^
17.860,40
-1,26%
Gold spot
2.313,58
-0,11%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers